Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency

Roberto Di Marco, Ming Xiang, Paola Zaccone, Camilla Leonardi, Sabrina Franco, Pierluigi Meroni, Ferdinando Nicoletti

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

One single intra-venous (i.v.) injection of Concanavalin A (Con A) into mice provokes a cell-mediated immunoinflammatory hepatitis. We have presently evaluated the immunopharmacological effects of exogenous interleukin (IL)-10 and the role of endogenous IL-10 in this model by using exogenous IL-10, anti-IL-10 monoclonal antibody (mAb) and mice with disrupted IL-10 gene (IL-10 KO mice). Whilst exogenous IL-10 administered in a prophylactic (1 h prior to Con A) and even 'early' therapeutic fashion (30 min after Con A) reduced the elevation of transaminase activities in plasma in a dose-dependent manner, observed in control mice, these biochemical markers of liver injury were significantly increased both in IL-10 KO mice as well as in those receiving anti-IL-10 mAb. Interestingly, doses of Con A lower than 20 mg/kg that were only capable of inducing slight serological signs of hepatitis in mice, exerted marked hepatitic effects when administered to either anti-IL-10 mAb-treated mice or to IL-10 KO mice. The disease modulating effects of exogenous IL-10 and either genetical or pharmacologically-induced IL-10 deficiency were associated with profound and opposite modifications of the Con A-induced increase in the circulating levels of IFN-γ and TNF-α. Relative to control animals, the blood levels of these cytokines were diminished in IL-10-treated mice and augmented in both IL-10 KO mice and anti-IL-10 mAb-treated mice. These results prove the physiological antiinflammatory role of endogenous IL-10 in Con A induced hepatitis and the beneficial effects of IL-10 treatment to prevent this condition.

Original languageEnglish
Pages (from-to)75-83
Number of pages9
JournalAutoimmunity
Volume31
Issue number2
Publication statusPublished - 1999

Fingerprint

Concanavalin A
Interleukin-10
Hepatitis
Monoclonal Antibodies
Transaminases

Keywords

  • Cytokines
  • Hepatitis
  • Immunotherapy
  • Interleukin-10

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Di Marco, R., Xiang, M., Zaccone, P., Leonardi, C., Franco, S., Meroni, P., & Nicoletti, F. (1999). Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity, 31(2), 75-83.

Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. / Di Marco, Roberto; Xiang, Ming; Zaccone, Paola; Leonardi, Camilla; Franco, Sabrina; Meroni, Pierluigi; Nicoletti, Ferdinando.

In: Autoimmunity, Vol. 31, No. 2, 1999, p. 75-83.

Research output: Contribution to journalArticle

Di Marco, R, Xiang, M, Zaccone, P, Leonardi, C, Franco, S, Meroni, P & Nicoletti, F 1999, 'Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency', Autoimmunity, vol. 31, no. 2, pp. 75-83.
Di Marco, Roberto ; Xiang, Ming ; Zaccone, Paola ; Leonardi, Camilla ; Franco, Sabrina ; Meroni, Pierluigi ; Nicoletti, Ferdinando. / Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. In: Autoimmunity. 1999 ; Vol. 31, No. 2. pp. 75-83.
@article{3ff68ebc4a5c4feeae7d07faf1e0d7f5,
title = "Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency",
abstract = "One single intra-venous (i.v.) injection of Concanavalin A (Con A) into mice provokes a cell-mediated immunoinflammatory hepatitis. We have presently evaluated the immunopharmacological effects of exogenous interleukin (IL)-10 and the role of endogenous IL-10 in this model by using exogenous IL-10, anti-IL-10 monoclonal antibody (mAb) and mice with disrupted IL-10 gene (IL-10 KO mice). Whilst exogenous IL-10 administered in a prophylactic (1 h prior to Con A) and even 'early' therapeutic fashion (30 min after Con A) reduced the elevation of transaminase activities in plasma in a dose-dependent manner, observed in control mice, these biochemical markers of liver injury were significantly increased both in IL-10 KO mice as well as in those receiving anti-IL-10 mAb. Interestingly, doses of Con A lower than 20 mg/kg that were only capable of inducing slight serological signs of hepatitis in mice, exerted marked hepatitic effects when administered to either anti-IL-10 mAb-treated mice or to IL-10 KO mice. The disease modulating effects of exogenous IL-10 and either genetical or pharmacologically-induced IL-10 deficiency were associated with profound and opposite modifications of the Con A-induced increase in the circulating levels of IFN-γ and TNF-α. Relative to control animals, the blood levels of these cytokines were diminished in IL-10-treated mice and augmented in both IL-10 KO mice and anti-IL-10 mAb-treated mice. These results prove the physiological antiinflammatory role of endogenous IL-10 in Con A induced hepatitis and the beneficial effects of IL-10 treatment to prevent this condition.",
keywords = "Cytokines, Hepatitis, Immunotherapy, Interleukin-10",
author = "{Di Marco}, Roberto and Ming Xiang and Paola Zaccone and Camilla Leonardi and Sabrina Franco and Pierluigi Meroni and Ferdinando Nicoletti",
year = "1999",
language = "English",
volume = "31",
pages = "75--83",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Concanavalin A-induced Hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency

AU - Di Marco, Roberto

AU - Xiang, Ming

AU - Zaccone, Paola

AU - Leonardi, Camilla

AU - Franco, Sabrina

AU - Meroni, Pierluigi

AU - Nicoletti, Ferdinando

PY - 1999

Y1 - 1999

N2 - One single intra-venous (i.v.) injection of Concanavalin A (Con A) into mice provokes a cell-mediated immunoinflammatory hepatitis. We have presently evaluated the immunopharmacological effects of exogenous interleukin (IL)-10 and the role of endogenous IL-10 in this model by using exogenous IL-10, anti-IL-10 monoclonal antibody (mAb) and mice with disrupted IL-10 gene (IL-10 KO mice). Whilst exogenous IL-10 administered in a prophylactic (1 h prior to Con A) and even 'early' therapeutic fashion (30 min after Con A) reduced the elevation of transaminase activities in plasma in a dose-dependent manner, observed in control mice, these biochemical markers of liver injury were significantly increased both in IL-10 KO mice as well as in those receiving anti-IL-10 mAb. Interestingly, doses of Con A lower than 20 mg/kg that were only capable of inducing slight serological signs of hepatitis in mice, exerted marked hepatitic effects when administered to either anti-IL-10 mAb-treated mice or to IL-10 KO mice. The disease modulating effects of exogenous IL-10 and either genetical or pharmacologically-induced IL-10 deficiency were associated with profound and opposite modifications of the Con A-induced increase in the circulating levels of IFN-γ and TNF-α. Relative to control animals, the blood levels of these cytokines were diminished in IL-10-treated mice and augmented in both IL-10 KO mice and anti-IL-10 mAb-treated mice. These results prove the physiological antiinflammatory role of endogenous IL-10 in Con A induced hepatitis and the beneficial effects of IL-10 treatment to prevent this condition.

AB - One single intra-venous (i.v.) injection of Concanavalin A (Con A) into mice provokes a cell-mediated immunoinflammatory hepatitis. We have presently evaluated the immunopharmacological effects of exogenous interleukin (IL)-10 and the role of endogenous IL-10 in this model by using exogenous IL-10, anti-IL-10 monoclonal antibody (mAb) and mice with disrupted IL-10 gene (IL-10 KO mice). Whilst exogenous IL-10 administered in a prophylactic (1 h prior to Con A) and even 'early' therapeutic fashion (30 min after Con A) reduced the elevation of transaminase activities in plasma in a dose-dependent manner, observed in control mice, these biochemical markers of liver injury were significantly increased both in IL-10 KO mice as well as in those receiving anti-IL-10 mAb. Interestingly, doses of Con A lower than 20 mg/kg that were only capable of inducing slight serological signs of hepatitis in mice, exerted marked hepatitic effects when administered to either anti-IL-10 mAb-treated mice or to IL-10 KO mice. The disease modulating effects of exogenous IL-10 and either genetical or pharmacologically-induced IL-10 deficiency were associated with profound and opposite modifications of the Con A-induced increase in the circulating levels of IFN-γ and TNF-α. Relative to control animals, the blood levels of these cytokines were diminished in IL-10-treated mice and augmented in both IL-10 KO mice and anti-IL-10 mAb-treated mice. These results prove the physiological antiinflammatory role of endogenous IL-10 in Con A induced hepatitis and the beneficial effects of IL-10 treatment to prevent this condition.

KW - Cytokines

KW - Hepatitis

KW - Immunotherapy

KW - Interleukin-10

UR - http://www.scopus.com/inward/record.url?scp=0033391153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033391153&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 75

EP - 83

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 2

ER -